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Abstract
Background: Myopathy with extrapyramidal signs (MPXPS) is an autosomal recessive mitochondrial disorder which
is caused by mutation in mitochondrial calcium uptake 1 (MICU1) gene located on chromosome 10q22.1. Next
Generation Sequencing (NGS) technology is the most effective method for identification of pathogenic variants
with the ability to overcome some limitations which Sanger sequencing may encountered. There are few reports
on this rare disease around the world and here in this study we first revealed genetic identification of two affected
individuals in an Iranian family with a novel mutation.
Case presentation: The proband was a 5-year-old girl from consanguenous parents. She was first clinically
suspicious of affected with limb-girdle muscular dystrophy (LGMD). Muscle biopsy studies and autozygosity
mapping, using four short tandem repeat (STR) markers linked to 6 genes of the most prevalent forms of LGMD,
ruled out calpainopathy, dysferlinopathy, and sarcoglycanopathis. DNA sample of the proband was sent for NGS.
Whole exome sequencing (WES) revealed a novel mutation c.1295delA in exon 13 of MICU1 gene. This
homozygous deletion creates a frameshift and a premature stop codon downstream of canonical EF4 calcium
binding motif of MICU1. According to the American College of Medical Genetics and Genomics (ACMG) guidline
for sequence interpretation, this variant was a pathogenic one. Sanger sequencing in all family members confirmed
the results of the WES.
Conclusions: This study was the first report of MPXPS in Iranian population which also revealed a novel mutation
in the MICU1 gene.
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Background
Myopathy with extrapyramidal signs (OMIM #615673)
is a rare autosomal recessive mitochondrial disorder
caused by mutations in MICU1 gene that typically
causes muscle weakness with normal respiratory chain
[1, 2]. MICU1 (OMIM #605084) which is also known as
CALC, EFHA3, MPXPS and CBARA1 gene, is located on
chromosome 10q22.1 and includes 17 exons [3–5]. This
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gene is translated into a 476 amino acid protein with ~
54 kDa molecular mass [6]. MICU1 protein is an inner
mitochondrial membrane (IMM) protein with three dis-
tinct regions: N-terminal domains (residues 1–32) con-
sisting of mitochondrial targeting sequence and MICU1/
MCU complex binding polybasic domain, a hydrophobic
transmembrane α-helix domain (TM) (residues 33–52),
and cytosolic C-terminal Ca2+ binding domain (residues
53–476) [6]. The X-ray crystallography of the Ca2+-free
MICU1 revealed that C-terminal domain is divided into
four constructs including the N-domain (aa ~ 103–177),
the N-lobe (aa ~ 183–318), the C-lobe (aa ~ 319–445),
and the C-helix (aa ~ 446–476) that canonical EF1 and
EF4 hands are responsible for binding to cytosolic Ca2+
which are located in the N-lobe and C-lobe, respectively
[6, 7].
Few studies showed pathogenic variants in the MICU1
gene in patients from European and middle East coun-
tries [1, 8, 9].
LGMD is a large heterogeneous group of neuromuscu-
lar disorders which can be transmitted in autosomal
dominant (LGMDD) and autosomal recessive (LGMDR)
manner [10, 11]. Common feature of LGMD disorders is
the progressive weakness of the shoulder girdle muscles
[11].
Autozygosity mapping is a good and practical ap-
proach in the gene tracking of heterogeneous disorders
in consanguineous families [12, 13]. Since the cost of
next generation sequencing continues to decreasethe
NGS will be widly used in identifying pathogenic vari-
ants [14].
In the present study, we investigated a family with two
affected children who were suspected of having LGMD,
but further pathologic and molecular studies using auto-
zygosity mapping and NGS provide us the final diagnosis
of a rare form of myopathy, Myopathy with extrapyram-
idal signs. To our knowledge it is the first report of this
disorder in Iran and it also showed a novel mutation in
causative gene, MICU1.
Case presentation
The proband was a 5-year-old girl who was referred to
Kawsar Human Genetics Research Center (KHGRC)
(Fig. 1). The affected proband had an affected sister and
they were born to second cousin parents. This research
has been performed in accordance with the Declaration
of Helsinki; Informed consent was obtained from all
family members and the study was approved by the eth-
ical committee of the Pasteur Institute of Iran (No: 91/
0201/10425). The proband was incidentally diagnosed
with raised CK (5175 U/L) prior to muscle biopsy at the
age of 5 but she was symptom free. Calf hypertrophy
was also observed in the proband but she was ambulant
at the age of 5 without positive Gowers sign. She showed
high levels of CK up to 5175 U/L (normal < 145), LDH
to 843 U/L and also increased level of ALT (105 U/L)
and AST (71 U/L). She also had poor weight gain. Heart
echocardiography showed a mild right side enlargement
and mild pericardial infusion. EMG/NCV (electromyog-
raphy and nerve condition velocity) study revealed short
duration MUAPs in two upper and lower extremities
tested muscles which was in favor of myopathic changes.
The proband was followed up and examined at the age
of 10 and she showed some extrapyramidal signs. The
proband’s sister was 2 years old who was normal in her
physical examination but showed elevated levels of CK
(3442 U/L), AST (136 U/L), ALT (73 U/L), and LDH
(799 U/L). Her EMG/NCV result was also normal. Both
of them, the proband and her sister, had speech delay.
Fig. 1 a Pedigree of the family with two affected children (filled symbols). b Sequence chromatograms of c.1294_1295delA mutation in the
affected proband V1 are shown in homozygous form (up) compared to heterozygous form (her mother (IV2) (down)). Site of the deletion is
shown with arrows
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According to their clinical examination and family his-
tory, the affected siblings were suspected to have LGMD.
Therefore, they were candidate of performing muscle bi-
opsy studies.
Muscle biopsy was performed on the proband at the
age of 5. Fresh muscle specimen was taken from left del-
toid of proband and quickly frozen in isopentane cooled
by liquid nitrogen. Standard panel of special histochem-
ical stains was used for sample analyzing [15]. Immuno-
histochemical staining was done using monoclonal
antibodies against dystrophin (1, 2, 3), sarcoglycans (α,
γ), dysferlin and merosin (Newcastle, UK). Beta-spectrin
was also applied as a positive control. All antibodies
were purchased from Novocastra Laboratories (Newcas-
tle, UK). Microscopic study of hematoxylin and eosin
(H&E) stains of tissue sections revealed slight variation
in fiber size and dispersed, round and angular atrophic
fibers with some small groups of necrotic or degenera-
tive/regenerative fibers with rare myophagocytosis.
Muscle fibers showed internalized nuclei but not prom-
inently increased and hypercontracted myofibers were
also seen (Fig. 2a). NADH-TR reaction revealed good
differentiation of muscle fibers. Overall intermyofibrillar
network seems regular (Fig. 2b). SDH reaction showed
no prominent abnormal mitochondrial proliferation.
Gomori-trichrome stains revealed no ragged-red-fiber.
No red or rimmed vacuole have been observed. (Fig. 2c).
ATPase histochemical reactions (at a PH of 9.4, 4.63,
and 4.35) revealed type 1 fibers predominance. Most
atrophic angular fibers were type 2, and no fiber type
grouping was observed (Fig. 3a). Immunohistochemistry
(IHC) staining of sarcolemmal proteins with monoclonal
antibodies against DYS (dystrophin) 1, 2, and 3, sarco-
glycans (α and γ), dysferlin, merosin and beta spectrin
showed that almost all fibers were labeled which is
suggestive of mild myopathic atrophy with few dispersed
or small groups of degenerative/regenerative fibers but
no endomysial fibrosis, no adipose tissue replacement,
and no inflammation (Fig. 3b-f).
Ruling out the most common forms of LGMD, haplo-
type analysis has been done. Salting out procedure was
used to extract genomic DNA from the peripheral blood
samples of all the family members [16]. Haplotype ana-
lysis was performed using four STR markers linked to
six genes of naming CAPN3, DYSF, SGCA, SGCB,
SGCG, and SGCD in two multiplex PCR sets for all fam-
ily members but no linkage was observed. Mutations in
the mentioned genes are responsible for the most preva-
lent form of limb-girdle muscular dystrophies. DNA se-
quencing, interpretation and fragment analysis were
done using methods described previously [17].
The blood sample of the proband was sent to Cento-
gene (Rostock, Germany) for whole exome sequencing
(WES) analysis. Enrichment was carried out using Nex-
tera Rapid Capture Exome kit following the manufac-
turer’s protocol (Nextera Rapid Capture Exome,
Illumina) and WES was performed by the Illumina
HiSeq 2500 system sequencing platform (Illumina, San
Diego, CA, USA) for DNA sequencing of the generated
enriched library to an average coverage depth 70-100X.
NGS results showed a novel homozygous deletion
c.1295delA in exon 13 of the MICU1 gene (NM_
006077.3) [1]. This variation leads to a frameshift and
cause premature stop codon in 8 following amino acids.
In order to interpret pathogenicity of variants and pre-
dicting their effect on the protein structure, different
software were used such as CADD (Combined Annota-
tion Dependent Depletion) [18] and Mutation Taster
[19]. According to the mutation taster, it is a disease
causing mutation and its CADD score is 35.
Fig. 2 Muscle biopsy studies of the patient V1 when sataining with H & E (a), NADH-TR (b), SDH (c). All figures are (× 400) magnification
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Confirming the results of the WES, the Sanger sequen-
cing was done in the proband and all her family mem-
bers. As it was expected, the variation was in
homozygous in two affected individuals and parents
were carrier for this variation (Fig. 1b). These results in-
dicated the co-segregation of the MICU1 gene variant
with the disease phenotype in this family. The timeline
for diagnosis of the proband in revealed in Table 1.
Discussion and conclusions
There is little information available about the patients
affected by myopathy with extrapyramidal signs world-
wide, which is due to its low prevalence and low clinical
specificity which cause overlapping clinical and patho-
logical features with other motor disorders [8], therefore
there are few reports available about this disorder. Logan
and his group studied 11 patients with MICU1 patho-
genic variants from five Pakistani families and 4 patients
from two Dutch families in 2014 [1]. In the other study,
2 MPXPS patients with identified mutations were re-
ported from the United Kingdom [8]. According to a
study from Qatar, 13 patients from 10 consanguineous
Middle Eastern Arab families showed recessive muta-
tions in the MICU1 [9].
Since consanguineous marriage is common in Iran,
autosomal recessive forms of LGMD is more prevalent,
therefore we ruled out the most common types of
LGMDR by IHC study and autozygosity mapping.
Thereupon we used NGS and found a novel deletion
mutation (c.1294-1295delA) in the exon 13 of the
MICU1 gene. This homozygous deletion produced a
premature stop codon which results in decreasing the
length of the protein from 478 to 438 amino acids
(p.Asn432Ilefs*8). The mutation located in the canonical
EF4 calcium binding motif of MICU1 protein. This motif
is located in the c-lobe presented in the intermembrane
space (IMS) of mitochondria and contains one helix-
loop-helix protein structure that has the ability to bind
to one Ca2+ ion, Therefore our identified mutation may
disrupt mitochondrial Ca2+ uptake [20–22]. Since amino
acid Cys 465 has a role in heterodimer formation with
MICU2 through a disulfide bond, removing this region
by the mutation observed in our patient can abolish this
function [23]. According to the joint consensus recom-
mendation of the ACMG for the interpretation of se-
quence variants [24], this variant is a pathogenic one
because of following evidences: 1. The nonsense and
frameshift mutations are in a null variants category
where they were predicted as a very strong evidence of
pathogenicity (PVS1), 2. Absence the variant from con-
trol in population databases such as Exome Sequencing
Project, 1000 Genomes Project, or Exome Aggregation
Consortium is a moderate evidence for pathogenicity
(PM2), 3. In-frame deletion in none repeat areas result-
ing changes in the protein length is considered a
Fig. 3 ATPase (the PH in this figure is 4.6) (a), DYS1 (b), DYS2 (c), Merosin (d), Alpha sarcoglycan (e), and Gamma sarcoglycan (f). All figures are
(× 400) magnification
Table 1 Timeline of diagnosis the proband
2012/06/25 Age at onset
2012/09/26 Physical examinations
2012/10/30 CK test and EMG/NCV
2012/12/05 Heart echocardiography
2013/07/27 Muscle biopsy study
2014/09/20 The first reffering for genetic diagnosis
2014/10/20 Autozygosity mapping
2016–2017 NGS analysis and Sanger sequencing
2017/03/05 Final Diagnoses
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moderate proof for pathogenicity (PM4), 4. Several or
various lines of computational data interpreted a dele-
terious effect on the gene (PP3), 5. The patient’s pheno-
types are highly close to MPXPS (PP4).
Few mutations have been reported to lead the disrup-
tion of MICU1 gene [25]. In a study by Logan et al. two
loss of function mutations, c.1078–1G > C and
c.7411G > A, located outside of the calcium binding
motif of MICU1 reported in a cohort of 15 patients from
10 families with the disease phenotype [1]. Another
study by Lewis-Smith et al. showed a homozygous dele-
tion of exon 1 of MICU1 in two cousins with no identifi-
able level of MICU1 protein in fibroblasts [8]. According
to the latest report of the disease by Musa et.al a non-
sense variant, c.553C > T (p.Q185*), was reported as a
homozygous status in 12 patients and compound hetero-
zygous in 1 patient that located in the N-terminal do-
main of MICU1 gene [9].
To our knowledge, it is the first report of a myopathic
patient with extrapyramidal signs from Iran and this pa-
tient has a novel mutation. Developing methods like
autozygosity mapping and NGS which needs only the
blood sample can overcome the limitations of invasive
techniques such as immunohistochemistry which needs
muscle biopsy sample. Since NGS is a high-throughput
method, it can investigate all exons of the patient and it
can conquer the limitation of autozygosity mapping
which is restricted to some special genes. But it is obvi-
ous, using these techniques all together can confirm our
diagnosis, specially application of haplotype analysis in
prenatal diagnosis as an indirect method of diagnosis
can corroborate our results.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s12881-020-01016-y.
Additional file 1. Sequencing data.
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